Free tool
FAERS Monitor: Rylaze
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761179 or its brand name (Rylaze, Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn). Reports on generic versions are filed under their own applications.
Reports
344
Serious
165
48% of reports
Hospitalization
103
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use33
- hyperammonaemia31
- febrile neutropenia28
- nausea26
- hypersensitivity21
- pancreatitis20
- urticaria19
- rash18
- vomiting17
- neutropenia15
- anaphylactic reaction14
- ammonia increased12
- herpes simplex11
- systemic candida11
- cerebral candidiasis10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 44 |
| 2023 | 69 |
| 2024 | 104 |
| 2025 | 84 |
| 2026 | 43 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,815 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cerebral candidiasisSignal | 10 | 122405.9 | 42056.8 | 368,231 |
| hyperammonaemiaSignal | 31 | 381.4 | 272.3 | 11,315 |
| systemic candidaSignal | 11 | 269.1 | 150.2 | 2,665 |
| ammonia increasedSignal | 12 | 144.1 | 82.6 | 1,562 |
| herpes simplexSignal | 11 | 103.7 | 57.9 | 1,017 |
| febrile neutropeniaSignal | 28 | 25.8 | 18.1 | 645 |
| pancreatitisSignal | 20 | 23.1 | 15.1 | 403 |
| anaphylactic reactionSignal | 14 | 15.5 | 9.3 | 176 |
| urticariaSignal | 19 | 6.9 | 4.5 | 91 |
| hypersensitivitySignal | 21 | 6.9 | 4.6 | 101 |
| neutropeniaSignal | 15 | 6.7 | 4.1 | 68 |
| rashSignal | 18 | 2.5 | 1.6 | 15 |
| off label useSignal | 33 | 2.3 | 1.7 | 24 |
| vomitingSignal | 17 | 2.2 | 1.4 | 10 |
| nauseaSignal | 26 | 2.0 | 1.4 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.